← Back to Clinical Trials
Recruiting NCT05427136

NCT05427136 Early Pulmonary Dysfunction in Childhood Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05427136
Status Recruiting
Phase
Sponsor University Children's Hospital Basel
Condition Pulmonary Dysfunction
Study Type OBSERVATIONAL
Enrollment 140 participants
Start Date 2021-06-01
Primary Completion 2051-06

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age 22 Years
Study Type OBSERVATIONAL
Interventions
Lung function measurementsBreath AnalysisMagnetic resonance imaging (MRI)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 140 participants in total. It began in 2021-06-01 with a primary completion date of 2051-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This longitudinal, prospective, multicentre study is to monitor lung function prospectively in childhood cancer patients after diagnosis. The impact of cancer treatment on pulmonary dysfunction non-invasively using lung function, lung imaging and breath analysis as well as clinical symptoms using a questionnaire will be assessed at different time points.

Eligibility Criteria

Inclusion Criteria: * at least one of the following cancer treatments: * chest radiation * treatment with any kind of chemotherapy * hematopoietic stem cell transplantation (HSCT) * thoracic surgery * consent for Childhood Cancer Registry (ChCR) registration Exclusion Criteria: * no signed informed consent * Operation outside the chest area as only cancer treatment * Relapsed cancer (patients who develop relapse during the study will not be excluded) * In addition for MRI and lung function tests: * Subjects who are respiratory insufficient and cannot perform a lung function test (less than 92% O2 saturation; under O2 therapy) * Pregnant * MRI measurement not possible without sedation * Metal (e.g. pacemaker) in the body

Contact & Investigator

Central Contact

Jakob Usemann, PD Dr. med.

✉ jakob.usemann@ukbb.ch

📞 +41 61 704 12 12

Principal Investigator

Jakob Usemann, PD Dr. med.

PRINCIPAL INVESTIGATOR

University Children's Hospital Basel

Frequently Asked Questions

Who can join the NCT05427136 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, up to 22 Years, studying Pulmonary Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05427136 currently recruiting?

Yes, NCT05427136 is actively recruiting participants. Contact the research team at jakob.usemann@ukbb.ch for enrollment information.

Where is the NCT05427136 trial being conducted?

This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Geneva, Switzerland, Lausanne, Switzerland and 1 additional location.

Who is sponsoring the NCT05427136 clinical trial?

NCT05427136 is sponsored by University Children's Hospital Basel. The principal investigator is Jakob Usemann, PD Dr. med. at University Children's Hospital Basel. The trial plans to enroll 140 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology